Xenos Mason, MD
Neurology · Los Angeles, CANPI 1619358801
Payments from drug & device makers
Across 130 payments — averaging $411.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$22K
- Janssen Research & Development, LLC$20K
- Boston Scientific$10K
- Medtronic$844
- Janssen Global Services, LLC$675
- Teva Pharmaceuticals USA, Inc.$154
- plus $26 from 2 others
What the payments were for
- Consulting fees$27,50351%
- Speaking & faculty fees$14,58827%
- Travel & lodging$6,61212%
- Food & beverage$4,6669%
- Education$830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 71 | $21,785 |
| Janssen Research & Development, LLC | 17 | $20,049 |
| Boston Scientific | 24 | $9,919 |
| Medtronic | 11 | $844 |
| Janssen Global Services, LLC | 1 | $675 |
| Teva Pharmaceuticals USA, Inc. | 2 | $154 |
| Cipher Pharmaceuticals US LLC | 1 | $23 |
| Travere Therapeutics, Inc. | 3 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARVYKTI$20,413
- INFINITY$19,703
- TECVAYLI$7,965
- VERCISE$1,763
- DARZALEX$675
- GENERAL DBS$652
- Proclaim Family of SCS IPGs$471
- PERCEPT PC BRAINSENSE$382
- Infinity DBS Pulse Generators$154
- Austedo XR$124
How this compares
$53,451 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 42 | $82,726 |
| MyrbetriqMirabegron | 20 | $18,589 |
| OngentysOpicapone | 14 | $14,724 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 49 | $4,570 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 80 | $3,681 |
| Rasagiline Mesylate | 29 | $3,427 |
| Entacapone | 14 | $1,841 |
| AmantadineAmantadine Hcl | 23 | $1,010 |
| Gabapentin | 16 | $593 |
| Fludrocortisone Acetate | 20 | $537 |
| Propranolol Hcl | 12 | $502 |
| Duloxetine Hcl | 11 | $287 |
| Tizanidine Hcl | 13 | $279 |
| Escitalopram Oxalate | 23 | $168 |
| Eszopiclone | 11 | $77 |
Paid to pharmacies, not to this prescriber.
Other neurology in Los Angeles
- Timothy CloughesyLos Angeles$33.1M
- Perry ShiehLos Angeles$8.2M
- Jeffrey SaverLos Angeles$2.9M
- David PiccioniLos Angeles$2.9M
- David LiebeskindLos Angeles$2.7M
- Michele TagliatiLos Angeles$2.5M
- Jennifer HuiLos Angeles$2.4M
- Susan PerlmanLos Angeles$2.2M
- Jeffrey CummingsLos Angeles$2M
- Bryan SpannLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.